Venture capital fundraising by biopharmaceutical companies plunged in the fourth quarter to $4.3bn, down from $6.2bn in the third quarter and below the $5.7bn raised in Q4 of 2022, according to the latest Venture Monitor report from Pitchbook and the National Venture Capital Association (NVCA). Full-year 2023 funding fell to $18.4bn, down from $24.5bn in 2022 for US-based companies.
The Pitchbook/NVCA numbers track with the most recent venture capital data tabulated by Evaluate, which showed $3.71bn raised globally in Q4, down from $4.28bn in Q3, with the annual total...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?